A New Component in the Mechanism of Regulation of Endogenous Depressive-Like States
- 8 Downloads
It was shown previously that cycloprolylglycine, an endogenous neuropeptide, is a positive AMPA receptor modulator and is able to increase the content of BDNF in neurons. In the present study, using the model of learned helplessness in rats, we showed that cycloprolylglycine at a dose of 1 mg/kg at subchronic intraperitoneal administration reduced the time of animal immobility to passive control values (from 167.6 to 83.6 s) on day 12 of the experiment. This indicates the presence of antidepressant-like activity. The results of the study allow us to consider cycloprolylglycine as a component in the physiological regulation of the depression-like state.
COMPLIANCE WITH ETHICAL STANDARDS
Conflict of interests. The authors declare that they have no conflict of interest.
Statement on the welfare of animals. All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
- 1.Gudasheva, T.A., Boyko, S.S., Akparov, V.Kh., Ostrovskaya, R.U., Skoldinov, A.P., Rozantsev, G.G., Voronina, T.A., Zherdev, V.P., and Seredenin, S.B., Identification of a novel endogenous memory facilitating cyclic dipeptide cyclo-prolylglycine in rat brain, FEBS Lett., 1996, vol. 391, pp. 149–152.CrossRefGoogle Scholar
- 2.Tran, L.H., Neuroprotection and neuroegenisis by administering cyclic prolyl glycine, US Patent no. 7232798, 2007.Google Scholar
- 3.Guan, J., Gluckman, P., Yang, P., Krissansen, G., Sun, X., Zhou, Y., Wen, J., Phillips, G., Shorten, P.R., McMahon, C.D., Wake, G.C., Chan, W.H.K., Tho-mas, M.F., Ren, A., Moon, S., and Liu, D.-X., Cyclic glycine-proline regulates IGF-1 homeostasis by altering the binding of IGFBP-3 to IGF-1, Sci. Rep., 2014, vol. 4, p. 4388.CrossRefGoogle Scholar
- 6.Povarnina, P.Yu., Koliasnikova, K.N., Nikolaev, S.V., Antipova, T.A., and Gudasheva, T.A., Cycloprolylglycine exhibits neuroprotective activity after systemic administration to rats with modeled incomplete global ischemia and in in vitro modeled glutamate neurotoxicity, Bull. Exp. Biol. Med., 2015, vol. 160, no. 11, pp. 653–655. https://doi.org/10.1007/sl0517-016-3241-5 CrossRefGoogle Scholar
- 7.Autry, A.E. and Monteggia, L.M., Brain-derived neurotrophic factor and neuropsychiatric disorders, Pharmacol. Rev., 2012, vol. 64, pp. 238–258. doi 11.005108 https://doi.org/10.1124/pr.l
- 8.Gudasheva, T.A., Koliasnikova, K.N., Antipova, T.A., and Seredenin, S.B., Neuropeptide cycloprolylglycine increases the levels of brain-derived neurotrophic factor in neuronal cells, Dokl. Biochem. Biophys., 2016, vol. 469, pp. 273–276. https://doi.org/10.1134/S1607672916040104 CrossRefPubMedGoogle Scholar
- 9.Gudasheva, T.A., Grigoriev, V.V., Kolyasnikova, K.N., Zamoyski, V.L., and Seredenin, S.B., Neuropeptide cycloprolylglycine is an endogenous positive modulator of AMPA receptors, Dokl. Biochem. Biophys., 2016, vol. 471, pp. 387–389. https://doi.org/10.1134/S160767291606003X CrossRefPubMedGoogle Scholar
- 13.Boiko, S.S., Ostrovskaya, R.U., Zherdev, V.P., Korotkov, S.A., Gudasheva, T.A., Voronina, T.A., and Seredenin, S.B., Pharmacokinetics of new nootropic acylprolyldipeptide and its penetration across the blood-brain barrier after oral administration, Bull. Exp. Biol. Med., 2000, vol. 129 no. 4, pp. 359–361.CrossRefGoogle Scholar
- 15.Karege, F., Vaudan, G., Schwald, M., Perroud, N., and La Harpe, R., Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs, Mol. Brain Res., 2005, vol. 136, nos. 1–2, pp. 29–37. https://doi.org/10.1016/j.molbrainres.2004.12.020 CrossRefPubMedGoogle Scholar